New study tests feel of HIV prevention gels during anal sex
NCT ID NCT02102867
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study involved 18 men and women who used three different rectal products (a gel, a cream, and a liquid) during anal sex and then rated their experience. The goal was to develop a questionnaire that captures how these products feel—like wetness, messiness, and pleasure—to help design better HIV prevention options. The study did not test whether the products prevent HIV, only how people perceive them.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
18 people
The number who actually took part.
- Start date
-
Apr 2014
- Finished
-
Apr 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * All participants must meet all of the inclusion criteria to participate in this study. * Eligible male participants must be 18 years of age or older * Eligible female participants must be 18-45 years of age Inclusion criteria include men and women who: * Report receptive anal intercourse (RAI) at least twice in the past 6 months, * Are willing to use each study product in conjunction with RAI on at least one occasion in each data collection period (resulting in a minimum of 3 RAI events during each product evaluation period; on average every 2 weeks, all 3 products across an average of 6 -12 weeks)) * Are willing and able to respond to study data collection systems via phone and internet, attend all study visits, and participate in in-depth qualitative interviews Exclusion Criteria: * Male and female participants will be ineligible if they: * Have a sensitivity or allergy to vaginal, anal, or rectal products, * Have a sensitivity or allergy to any of the ingredients contained in the study products, * Are HIV positive at baseline, or have a known HIV-positive sexual partner, * Have an active rectal or reproductive tract infection requiring treatment per current Centers for Disease Control (CDC) guidelines or symptomatic urinary tract infection (UTI). Infections requiring treatment include Chlamydia (CT)\*, gonorrhea (GC)\*, syphilis, active herpes simplex virus (HSV) lesions (note: HSV seropositivity with no active genital lesions is not an exclusion criterion, since treatment is not required), chancroid, genital sores or ulcers, and, if clinically indicated, genital warts, * Have current inflammatory bowel disease (IBD) or history of active IBD within last 3 months, * Have any other significant colorectal symptom(s) as determined by medical history, participant self-report , or physical exam (including but not limited to presence of any unresolved injury, infectious or inflammatory condition of the local mucosa, presence of symptomatic external hemorrhoids, and presence of any painful anorectal conditions that would be tender to manipulation), * Have a nontreatable sexually transmitted disease that could, in the opinion of the investigator/study clinician, make the patient unsuitable for the study or unable to comply with study requirements * Have any other clinical condition or prior therapy that, in the opinion of the investigator/study clinician, would make the patient unsuitable for the study or unable to comply with the study requirements, * Are unwilling to refrain from use of nonoxynol-9 (N9) for the duration of the study, * Are unable or unwilling to communicate in English, or * Are unable or unwilling to give written informed consent. Additionally, female participants will be ineligible if they: • Are pregnant or breastfeeding.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Microbicide delivery system perceptibility and acceptability are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Miriam Hospital: Centers for Behavioral & Preventive Medicine
Providence, Rhode Island, 02903, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.